JY
RANI icon

Jeff Yass’s Rani Therapeutics RANI Stock Holding History

Jeff Yass’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3K Sell
21,400
-25,700
-55% -$22.8K ﹤0.01% 13078
2026
Q1 		$34.4K Sell
47,100
-126,800
-73% -$162K ﹤0.01% 12732
2025
Q4 		$235K Buy
+173,900
New +$262K ﹤0.01% 10515

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jeff Yass's RANI Position: Q2 2026 in Review

Jeff Yass reduced its Rani Therapeutics (RANI) stake by 69% in Q2 2026, selling an estimated $116K and leaving 57,790 shares worth $43.9K. The position accounts for ﹤0.01% of the portfolio, ranked #12875.

Jeff Yass first reported a position in RANI in Q1 2023 and has held it in 5 quarters since. The position peaked at $365K in Q1 2023. 67 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Jeff Yass held 57,790 shares of Rani Therapeutics worth $43.9K as of Q2 2026.
  • Jeff Yass sold 130,432 Rani Therapeutics shares in Q2 2026, an estimated $116K.
  • Rani Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12875 holding.
  • Jeff Yass first reported a position in Rani Therapeutics in Q1 2023 and has held it in 5 quarters since.
  • Jeff Yass's Rani Therapeutics position peaked at $365K in Q1 2023.
  • 67 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.